Literature DB >> 28598310

In vitro activities of vancomycin and linezolid against biofilm-producing methicillin-resistant staphylococci species isolated from catheter-related bloodstream infections from an Egyptian tertiary hospital.

Asmaa A Hashem1, Noha M Abd El Fadeal2, Atef S Shehata3,1.   

Abstract

PURPOSE: Catheter-related bloodstream infections (CRBSIs) are among the most common hospital-acquired infections. We aimed to survey methicillin resistance, biofilm production and susceptibility to vancomycin, linezolid and other antibiotics for staphylococci isolated from CRBSIs.
METHODOLOGY: Fifty-eight isolates [20 S. aureus and 38 coagulase-negative staphylococci (CoNS; 20 Staphylococcusepidermidis, nine Staphylococcushaemolyticus, three Staphylococcusschleiferi, two Staphylococcuswarneri and four Staphylococcuslugdunensis)] were tested for methicillin resistance by cefoxitin disk diffusion and detection of the mecA gene by PCR; biofilm-forming ability using Congo red agar and tissue culture plate methods; susceptibility to ciprofloxacin, clindamycin, cotrimoxazole, erythromycin, gentamicin, linezolid, rifampicin and tetracycline; and MIC determination for vancomycin.Results/Key findings. Cefoxitin resistance was detected among 40 % (8/20) S. aureus isolates, 70 % (14/20) S. epidermidis isolates and 16.7 % (3/18) of other CoNS, although the mecA gene was detected in 45 % (9/20) S. aureus isolates, 35 % (7/20) S. epidermidis isolates and 16.7 % (3/18) of other CoNS. Biofilm-forming ability ranged from 45 to 75 %. Methicillin-resistant S. aureus and other CoNS were considered to be more virulent than methicillin-resistant S. epidermidis due to the higher biofilm forming abilities of the former. All tested isolates exhibited 100 % sensitivity to vancomycin and linezolid, irrespective of their methicillin resistance or biofilm-forming ability. Rifampicin showed overall sensitivity of 75.9 %. Varying degrees of multi-resistance were found for the other antibiotics.
CONCLUSION: Vancomycin, linezolid and rifampicin could be used effectively against methicillin-resistant staphylococci isolated from CRBSIs.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28598310     DOI: 10.1099/jmm.0.000490

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  6 in total

1.  Prevalence and mechanisms of linezolid resistance among staphylococcal clinical isolates from Egypt.

Authors:  Lina Maarouf; Hoda Omar; Moustafa El-Nakeeb; Alaa Abouelfetouh
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2020-10-26       Impact factor: 3.267

2.  Emergence of linezolid-resistant Staphylococcus epidermidis in the tertiary children's hospital in Cracow, Poland.

Authors:  Maja Kosecka-Strojek; Ewa Sadowy; Iwona Gawryszewska; Joanna Klepacka; Tomasz Tomasik; Michal Michalik; Waleria Hryniewicz; Jacek Miedzobrodzki
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2020-04-29       Impact factor: 3.267

3.  Detection of Biofilm Producing Staphylococci among Different Clinical Isolates and Its Relation to Methicillin Susceptibility.

Authors:  Rania M Abdel Halim; Nevine N Kassem; Basma S Mahmoud
Journal:  Open Access Maced J Med Sci       Date:  2018-08-05

4.  Biofilm-Forming by Carbapenem Resistant Enterobacteriaceae May Contribute to the Blood Stream Infection.

Authors:  Kenichiro Yaita; Kenji Gotoh; Ryuichi Nakano; Jun Iwahashi; Yoshiro Sakai; Rie Horita; Hisakazu Yano; Hiroshi Watanabe
Journal:  Int J Mol Sci       Date:  2019-11-26       Impact factor: 5.923

5.  The In Vitro Antimicrobial and Antibiofilm Activities of Lysozyme against Gram-Positive Bacteria.

Authors:  Fang Liu; Xing Wang; Lijie Huang; Xinling Wang; Lili Kong; Jinyou Duan; Xiaoli Zhang; Haibo Mu; Jianguo He
Journal:  Comput Math Methods Med       Date:  2022-08-10       Impact factor: 2.809

6.  Antimicrobial resistance among GLASS pathogens in conflict and non-conflict affected settings in the Middle East: a systematic review.

Authors:  Claudia Truppa; Mahmoud N Abo-Shehada
Journal:  BMC Infect Dis       Date:  2020-12-09       Impact factor: 3.667

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.